NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...
MedPage Today on MSN
Drug Combo Lowers Albuminuria in High-Risk Chronic Kidney Disease
Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback